Testing for HIV drug resistance is essential to the care of HIV-infected patients. Although direct phenotypic resistance assays are highly reliable, the current recombinant virus-based method is costly and time-consuming. Here, we report a novel fluorometric assay for phenotypic differentiation of drug-resistant mutants of human immunodeficiency virus-I protease (HIV-PR) which uses enzymatic and peptide-specific fluorescence (FL) reactions and high-performance liquid chromatography (HPLC) of three HIV-PR substrates. This assay enables the use of non-purified enzyme sources and multiple substrates for the enzymatic reaction. In this study, susceptibility of HIV mutations to drugs was evaluated by selective formation of three FL products after the enzymatic HIV-PR reaction. This proof-of-concept study indicates that the present HPLC-FL method could be an alternative to current phenotypic assays for the evaluation of HIV drug resistance.
Previous Article in event
Next Article in event
Convenient drug-resistance testing of HIV mutants
Published: 02 November 2015 by MDPI in 1st International Electronic Conference on Medicinal Chemistry session ECMC-1
Keywords: drug-resistance testing; HIV; protease; phenotypic; fluorometric; HPLC